Tung-Hu Tsai1, Yu-Jen Chen2, Mei-Ling Hou3, Li-Ying Wang4, Hung-Chi Tai5, Chen-Hsi Hsieh6. 1. Institute of Traditional Medicine, School of Medicine, National Yang-Ming University Taipei, Taiwan ; Department of Education and Research, Taipei City Hospital Taipei, Taiwan. 2. Institute of Traditional Medicine, School of Medicine, National Yang-Ming University Taipei, Taiwan ; Department of Radiation Oncology, Mackay Memorial Hospital Taipei, Taiwan ; Department of Medical Research, Mackay Memorial Hospital Taipei, Taiwan. 3. Institute of Traditional Medicine, School of Medicine, National Yang-Ming University Taipei, Taiwan. 4. School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University Taipei, Taiwan. 5. Department of Radiation Oncology, Mackay Memorial Hospital Taipei, Taiwan. 6. Institute of Traditional Medicine, School of Medicine, National Yang-Ming University Taipei, Taiwan ; Department of Medicine, School of Medicine, National Yang-Ming University Taipei, Taiwan ; Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital Taipei, Taiwan.
Abstract
BACKGROUND: Cisplatin (CDDP) is employed to enhance radiotherapy's (RT) effect for various cancers. However, the effects of local RT on chemotherapeutics in the plasma and lymphatic system remain unclear. Here, we evaluated the influence of pelvic irradiation on the pharmacokinetics (PK) of CDDP using rats as an experimental model. METHODS AND MATERIALS: RT with 2 Gy and 0.5 Gy were delivered to the whole pelvis of Sprague-Dawley rats. CDDP at 5 mg/kg and 10 mg/kg was intravenously infused 24 hours after radiation for the plasma and lymphatic system, respectively. The pharmacokinetics of CDDP in the plasma and lymphatic system were calculated. RESULTS: Compared with sham-irradiated controls, the whole pelvic irradiation increased the area under the concentration versus time curve (AUC) of CDDP (5 mg/kg) in the plasma by 80% at 0.5 Gy and 87% at 2 Gy, respectively. In contrast, the AUC of CDDP decreased in bile by 13% at both dose levels. Intriguingly, RT could also increase the AUC of CDDP (10 mg/kg) in the lymphatic fluid by 87% at 2 Gy. In addition, the AUC in CDDP without and with RT was 2.8-fold and 3.4-fold greater for the lymph system than for the plasma, respectively. CONCLUSIONS: A local pelvic RT could modulate the systemic PK of CDDP in both the plasma and lymphatic fluids of the rats. The RT-PK phenomena are worth further investigation.
BACKGROUND:Cisplatin (CDDP) is employed to enhance radiotherapy's (RT) effect for various cancers. However, the effects of local RT on chemotherapeutics in the plasma and lymphatic system remain unclear. Here, we evaluated the influence of pelvic irradiation on the pharmacokinetics (PK) of CDDP using rats as an experimental model. METHODS AND MATERIALS: RT with 2 Gy and 0.5 Gy were delivered to the whole pelvis of Sprague-Dawley rats. CDDP at 5 mg/kg and 10 mg/kg was intravenously infused 24 hours after radiation for the plasma and lymphatic system, respectively. The pharmacokinetics of CDDP in the plasma and lymphatic system were calculated. RESULTS: Compared with sham-irradiated controls, the whole pelvic irradiation increased the area under the concentration versus time curve (AUC) of CDDP (5 mg/kg) in the plasma by 80% at 0.5 Gy and 87% at 2 Gy, respectively. In contrast, the AUC of CDDP decreased in bile by 13% at both dose levels. Intriguingly, RT could also increase the AUC of CDDP (10 mg/kg) in the lymphatic fluid by 87% at 2 Gy. In addition, the AUC in CDDP without and with RT was 2.8-fold and 3.4-fold greater for the lymph system than for the plasma, respectively. CONCLUSIONS: A local pelvic RT could modulate the systemic PK of CDDP in both the plasma and lymphatic fluids of the rats. The RT-PK phenomena are worth further investigation.
Authors: R Pearcey; M Brundage; P Drouin; J Jeffrey; D Johnston; H Lukka; G MacLean; L Souhami; G Stuart; D Tu Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Rachelle Lanciano; Alison Calkins; Brian N Bundy; Groesbeck Parham; Joseph A Lucci; David H Moore; Bradley J Monk; Dennis M O'Connor Journal: J Clin Oncol Date: 2005-10-17 Impact factor: 44.544
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Mitchell R McGill; David L Findley; Anna Mazur; Eric U Yee; Felicia D Allard; Allison Powers; Lori Coward; Eric R Blough; Greg Gorman; Michael D Hambuchen Journal: Eur J Drug Metab Pharmacokinet Date: 2022-02-08 Impact factor: 2.441
Authors: Alfonso Toro-Córdova; Fabricio Ledezma-Gallegos; Laura Mondragon-Fuentes; Rafael Jurado; Luis A Medina; Jazmin M Pérez-Rojas; Patricia Garcia-Lopez Journal: J Chromatogr Sci Date: 2016-03-24 Impact factor: 1.618